Merck (MRK) Accounts Payables (2009 - 2026)
Merck (MRK) reported Accounts Payables of $3.9 billion for Q1 2026, up 2.09% year-over-year from $3.8 billion in Q1 2025, and down 12.28% on a QoQ basis from $4.4 billion in Q4 2025.
Merck (MRK) has 18 years of Accounts Payables data on file, last reported at $3.9 billion in Q1 2026.
- Quarterly Accounts Payables rose 2.09% year-over-year to $3.9 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.9 billion (up 2.09% YoY) and the FY2025 annual result came in at $4.4 billion, up 7.97% from the prior year.
- Accounts Payables eased to $3.9 billion in Q1 2026 per MRK's latest filing, from $4.4 billion in the prior quarter.
- Across five years, Accounts Payables topped out at $4.4 billion in Q4 2025 and bottomed at $3.4 billion in Q3 2022.
- The 5-year median for Accounts Payables is $3.7 billion (2022), against an average of $3.8 billion.
- The widest annual swing landed in 2022, when Accounts Payables retreated 10.65%; it then gained 15.64% in 2025.
- Tracing MRK's Accounts Payables over 5 years: stood at $4.3 billion in 2022, then slipped by 8.02% to $3.9 billion in 2023, then increased by 4.0% to $4.1 billion in 2024, then gained by 7.97% to $4.4 billion in 2025, then dropped by 12.28% to $3.9 billion in 2026.
- Per Business Quant, the three latest MRK Accounts Payables figures stand at $3.9 billion (Q1 2026), $4.4 billion (Q4 2025), and $4.1 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 5.03 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 10.46 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 33.77 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 3.86 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 2.94 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 645.00 Mn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 4.51 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 4.23 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 20.46 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.86 Bn |
| Dec 31, 2025 | 4.40 Bn |
| Sep 30, 2025 | 4.15 Bn |
| Jun 30, 2025 | 3.89 Bn |
| Mar 31, 2025 | 3.78 Bn |
| Dec 31, 2024 | 4.08 Bn |
| Sep 30, 2024 | 3.59 Bn |
| Jun 30, 2024 | 3.52 Bn |
| Mar 31, 2024 | 3.51 Bn |
| Dec 31, 2023 | 3.92 Bn |
| Sep 30, 2023 | 3.51 Bn |
| Jun 30, 2023 | 3.44 Bn |
| Mar 31, 2023 | 3.68 Bn |
| Dec 31, 2022 | 4.26 Bn |
| Sep 30, 2022 | 3.37 Bn |
| Jun 30, 2022 | 3.48 Bn |
| Mar 31, 2022 | 3.72 Bn |
| Dec 31, 2021 | 4.61 Bn |
| Sep 30, 2021 | 3.37 Bn |
| Jun 30, 2021 | 3.90 Bn |
| Mar 31, 2021 | 4.03 Bn |
| Dec 31, 2020 | 4.33 Bn |
| Sep 30, 2020 | 3.74 Bn |
| Jun 30, 2020 | 3.45 Bn |
| Mar 31, 2020 | 3.57 Bn |
| Dec 31, 2019 | 3.74 Bn |
| Sep 30, 2019 | 3.20 Bn |
| Jun 30, 2019 | 3.14 Bn |
| Mar 31, 2019 | 3.02 Bn |
| Dec 31, 2018 | 3.32 Bn |
| Sep 30, 2018 | 3.09 Bn |
| Jun 30, 2018 | 3.02 Bn |
| Mar 31, 2018 | 3.16 Bn |
| Dec 31, 2017 | 3.10 Bn |
| Sep 30, 2017 | 2.62 Bn |
| Jun 30, 2017 | 2.93 Bn |
| Mar 31, 2017 | 2.48 Bn |
| Dec 31, 2016 | 2.81 Bn |
| Sep 30, 2016 | 2.48 Bn |
| Jun 30, 2016 | 2.51 Bn |
| Mar 31, 2016 | 2.24 Bn |
| Dec 31, 2015 | 2.53 Bn |
| Sep 30, 2015 | 2.02 Bn |
| Jun 30, 2015 | 2.34 Bn |
| Mar 31, 2015 | 2.09 Bn |
| Dec 31, 2014 | 2.63 Bn |
| Sep 30, 2014 | 2.28 Bn |
| Jun 30, 2014 | 2.33 Bn |
| Mar 31, 2014 | 2.43 Bn |
| Dec 31, 2013 | 2.27 Bn |
| Sep 30, 2013 | 2.47 Bn |
| Jun 30, 2013 | 2.25 Bn |
| Dec 31, 2012 | 1.75 Bn |
| Jun 30, 2012 | 1.67 Bn |
| Mar 31, 2012 | 2.36 Bn |
| Dec 31, 2011 | 2.02 Bn |
| Sep 30, 2011 | 2.28 Bn |
| Jun 30, 2011 | 2.14 Bn |
| Mar 31, 2011 | 2.40 Bn |
| Dec 31, 2010 | 2.31 Bn |
| Sep 30, 2010 | 2.24 Bn |
| Jun 30, 2010 | 2.17 Bn |
| Mar 31, 2010 | 2.07 Bn |
| Dec 31, 2009 | 2.24 Bn |
| Sep 30, 2009 | 1.71 Bn |
| Jun 30, 2009 | 1.76 Bn |